Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Saudi Food and Drug Authority (SFDA) has approved PYRUKYND^® (mitapivat) for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

Read more at globenewswire.com